BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen J, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TWT, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-smith G, Lawrance IC, Mclachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther 2016;44:127-44. [DOI: 10.1111/apt.13670] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Jain S, Ahuja V, Limdi JK. Optimal management of acute severe ulcerative colitis. Postgrad Med J. 2019;95:32-40. [PMID: 30636193 DOI: 10.1136/postgradmedj-2018-136072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
2 Li JR, Ling FM, Chen YD, Xu MY, Zhu LR. Treatment of acute severe ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2021; 29(2): 87-92 [DOI: 10.11569/wcjd.v29.i2.87] [Reference Citation Analysis]
3 Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;46:1037-53. [PMID: 29027257 DOI: 10.1111/apt.14368] [Cited by in Crossref: 144] [Cited by in F6Publishing: 117] [Article Influence: 28.8] [Reference Citation Analysis]
4 Liu S, Eisenstein S. State-of-the-art surgery for ulcerative colitis. Langenbecks Arch Surg 2021;406:1751-61. [PMID: 34453611 DOI: 10.1007/s00423-021-02295-6] [Reference Citation Analysis]
5 Dulai PS, Jairath V. A Microsimulation Model to Project the 5-Year Impact of Using Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Acute Flares. Dig Dis Sci 2021;66:3740-52. [PMID: 33185788 DOI: 10.1007/s10620-020-06707-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:56-66. [PMID: 29889235 DOI: 10.1093/ibd/izy208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 451] [Article Influence: 205.7] [Reference Citation Analysis]
8 Argollo MC, Kotze PG, Spinelli A, Gomes TN, Danese S. The impact of biologics in surgical outcomes in ulcerative colitis. Best Practice & Research Clinical Gastroenterology 2018;32-33:79-87. [DOI: 10.1016/j.bpg.2018.05.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
9 Shen M, Meng L. Peripheral blood miR-372 as a biomarker for ulcerative colitis via direct targeting of NLRP12. Exp Ther Med 2019;18:1486-92. [PMID: 31363381 DOI: 10.3892/etm.2019.7707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol 2018;32-33:59-69. [PMID: 30060940 DOI: 10.1016/j.bpg.2018.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
11 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Chu TPC, Grainge MJ, Card TR. The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity. Aliment Pharmacol Ther 2018;48:1099-108. [PMID: 30294897 DOI: 10.1111/apt.15010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
13 Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med 2019;8:E2169. [PMID: 31817972 DOI: 10.3390/jcm8122169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654-664. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
15 Carvello M, Watfah J, Włodarczyk M, Spinelli A. The Management of the Hospitalized Ulcerative Colitis Patient: the Medical-Surgical Conundrum. Curr Gastroenterol Rep 2020;22:11. [PMID: 32040642 DOI: 10.1007/s11894-020-0750-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Scribano ML, Papi C, Costa F, Bortoli A, Bortoluzzi F, Buscarini E, Cappello M, Caserta L, Cortelezzi C, Ferronato A, Manguso F, Mazzuoli S, Orzes N, Kohn A; AIGO IBD Study Group. Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study. Dig Liver Dis 2019;51:346-51. [PMID: 30195815 DOI: 10.1016/j.dld.2018.08.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL; Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. J Gastroenterol Hepatol 2019;34:1296-315. [PMID: 30848854 DOI: 10.1111/jgh.14648] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
18 Holvoet T, Lobaton T, Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol 2021;14:71-81. [PMID: 33727846 DOI: 10.2147/CEG.S197719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sedano R, Quera R, Simian D, Yarur AJ. An approach to acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2019;13:943-55. [PMID: 31648574 DOI: 10.1080/17474124.2019.1681974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
20 Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018;9:65-72. [PMID: 29387331 DOI: 10.1177/2040622317742095] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
21 Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45:617-630. [PMID: 28074618 DOI: 10.1111/apt.13913] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
22 Kim YH, Pfaller B, Marson A, Yim HW, Huang V, Ito S. The risk of venous thromboembolism in women with inflammatory bowel disease during pregnancy and the postpartum period: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e17309. [PMID: 31568016 DOI: 10.1097/md.0000000000017309] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
23 Goldowsky A, Sen R, Hoffman G, Feuerstein JD. Is there a standardized practice for the development of international ulcerative colitis and Crohn's disease treatment guidelines? Gastroenterol Rep (Oxf) 2021;9:408-17. [PMID: 34733526 DOI: 10.1093/gastro/goab009] [Reference Citation Analysis]
24 McKechnie T, Ramji K, Kruse C, Jaffer H, Rebello R, Amin N, Doumouras AG, Hong D, Eskicioglu C. Posterior mesorectal thickness as a predictor of increased operative time in rectal cancer surgery: a retrospective cohort study. Surg Endosc 2021. [PMID: 34382121 DOI: 10.1007/s00464-021-08674-w] [Reference Citation Analysis]
25 Horgan L, Mulrennan S, D'Orsogna L, McLean-Tooke A. Tracheobronchitis in ulcerative colitis: a case report of therapeutic response with infliximab and review of the literature. BMC Gastroenterol. 2019;19:171. [PMID: 31675916 DOI: 10.1186/s12876-019-1091-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Pitman S, Jones C, Polyak S, Taylor A, Cerven-jenn D, Reist D. Exploring Cost Savings with Specialty Biologic Drugs Administered to Adult Inpatients with Inflammatory Bowel Disease. Hosp Pharm. [DOI: 10.1177/0018578720985430] [Reference Citation Analysis]
27 Raval M, Choy MC, De Cruz P. Salvage therapy for acute severe ulcerative colitis during pregnancy. BMJ Case Rep 2018;2018:bcr-2017-223540. [PMID: 29884712 DOI: 10.1136/bcr-2017-223540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
29 McCurdy JD, Israel A, Hasan M, Weng R, Mallick R, Ramsay T, Carrier M. A clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49:1493-1501. [PMID: 31066471 DOI: 10.1111/apt.15286] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
30 Iacucci M, Cannatelli R, Labarile N, Mao R, Panaccione R, Danese S, Kochhar GS, Ghosh S, Shen B. Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. Lancet Gastroenterol Hepatol 2020;5:598-606. [PMID: 32305075 DOI: 10.1016/S2468-1253(20)30119-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 21.0] [Reference Citation Analysis]
31 Ko Y, Paramsothy S, Yau Y, Leong RW. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Aliment Pharmacol Ther 2021;54:292-301. [PMID: 34151447 DOI: 10.1111/apt.16436] [Reference Citation Analysis]
32 Moghadamyeghaneh Z, Rahimi M, Kopatsis K, Kopatsis AP, Kopatsis A. Minimally Invasive Surgical Approach to Toxic Colitis. Am Surg 2022;:31348221080420. [PMID: 35331011 DOI: 10.1177/00031348221080420] [Reference Citation Analysis]
33 Wu N, Mah C, Koentgen S, Zhang L, Grimm MC, El-Omar E, Hold GL. Inflammatory bowel disease and the gut microbiota. Proc Nutr Soc 2021;:1-11. [PMID: 34165053 DOI: 10.1017/S002966512100197X] [Reference Citation Analysis]
34 Leong RW, Katelaris PH. Positioning biologics-A case-based discussion: Anti-tumor necrosis factor biological agents/biosimilars: Positioning biologics-A case-based discussion: Anti-tumor necrosis factor biological agents/biosimilars. Journal of Gastroenterology and Hepatology 2018;33:14-14. [DOI: 10.1111/jgh.14421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Kobayashi T, Hisamatsu T, Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto T, Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa T, Sasaki M, Yokoyama K, Yoshimura N, Watanabe K, Katafuchi M, Watanabe M, Hibi T. Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. Intest Res 2018;16:168-77. [PMID: 29743830 DOI: 10.5217/ir.2018.16.2.168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
36 Zagórowicz E, Przybysz A, Szlak J, Magdziak A, Wieszczy P, Mróz A. Detection of cytomegalovirus by immunohistochemistry of colonic biopsies and quantitative blood polymerase chain reaction: evaluation of agreement in ulcerative colitis. Scand J Gastroenterol 2018;53:435-41. [PMID: 29513050 DOI: 10.1080/00365521.2018.1447596] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
37 Bernardo S, Fernandes SR, Gonçalves AR, Valente A, Baldaia C, Santos PM, Correia LA. Predicting the Course of Disease in Hospitalized Patients With Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:541-6. [PMID: 30085135 DOI: 10.1093/ibd/izy256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
38 Leong RW. Risk mitigation in Crohn's disease and ulcerative colitis: Session four summary. J Gastroenterol Hepatol 2021;36 Suppl 1:27-8. [PMID: 33817847 DOI: 10.1111/jgh.15456] [Reference Citation Analysis]
39 Ma J, Yin G, Lu Z, Xie P, Zhou H, Liu J, Yu L. Casticin prevents DSS induced ulcerative colitis in mice through inhibitions of NF-κB pathway and ROS signaling: Casticin prevents UC through inhibitions of NF-kB and ROS signaling. Phytotherapy Research 2018;32:1770-83. [DOI: 10.1002/ptr.6108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
40 Choy MC, Seah D, Faleck DM, Shah SC, Chao CY, An YK, Radford-Smith G, Bessissow T, Dubinsky MC, Ford AC, Churilov L, Yeomans ND, De Cruz PP. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1169-86. [PMID: 30605549 DOI: 10.1093/ibd/izy383] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
41 Ivashkin VT, Shelygin YA, Belousova EA, Abdulganieva DI, Alekseeva OA, Achkasov SI, Valuiskikh EY, Vardanyan AV, Veselov AV, Veselov VV, Golovenko OV, Gubonina IV, Zhigalova TN, Kashnikov VN, Knyazev OV, Makarchuk PA, Moskaliev AI, Nanaeva BA, Nizov AA, Nikitina NV, Nikolaeva NN, Pavlenko VV, Poluektova EA, Svetlova IO, Tarasova LV, Tkachev AV, Frolov SA, Khlynova OV, Chashkova EY, Shapina MV, Sheptulin AA, Shifrin OS, Shchukina OB. PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS. Koloproktologiâ 2019;18:7-36. [DOI: 10.33878/2073-7556-2019-18-4-7-36] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 5.3] [Reference Citation Analysis]
42 Haifer C. Catastrophe prevention: Acute severe ulcerative colitis. J Gastroenterol Hepatol 2021;36 Suppl 1:34. [PMID: 33817843 DOI: 10.1111/jgh.15459] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]